Fundamental Analysis of CytomX Therapeutics Inc - Growth / Value Index


CTMX - Valuation Highlights

Valuation Analysis

   Price to Earning Ratio is 8.73 and EV to EBITDA is 7.97 suggesting company is undervalued.
   Book value is negative
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 8.50 -13701.76 -1095140.05 %
Price to Book -2.33 -2940.07 -202811.47 % -4.93
Price to Sales 1.18 1472.58 62908.35 %
Enterprise Value to EBITDA Multiple 8.97 -17692.16 -2687603.60 %


CTMX - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Good Score of 71.53
   Earning Yield of 11.46 %
   Company Earning excess return
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Good Return On Capital Employed of 21.46
   Good Net Margin of 13.87% is achieved by the company
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 0 0 0 % 0
Return On Asset 7.86 -5.05 86.75 % 7.47
Net Profit Margin 13.87 -10.75 94.25 % 33.26
Operating Profit Margin 9.08 -16.24 91.48 % 28.11
EBITDA Margin 12.60 -8.32 95.54 % 28.11


Highlights
Market Cap147267 K
Enterprise Value134685 K
Price/Book TTM-2.33
Outstanding Share77919.40 K
Float/ Outstanding Share79.49%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score-4.20
Sloan Ratio0.125
Peter Lynch Fair Value5.56


CTMX - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   STRONG JUMP IN NET SALE : YoY growth
   Quarterly sales in last 5 years is trending up
   Tsr Growth Index - Poor Score of 25.38
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 119178 K 78.19 % 55.83 %
Gross Profit 118692 K 171.26 % 58.73 %
EBITDA 15016.00 K 92.05 % 781.10 %
Net Profit 16533.00 K 89.75 % 1547.67 %
EPS 0.222 99.99 % NA


CTMX - Stability Highlights

Stability Analysis

   Debt to equity ratio has decreased and is lowest in last five years
   Tsr Stability Index - Very Poor Score of 5.00
   Altman Z Score of -4.24 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio -0.097 -103.18 % -0.149
Cash Ratio 1.12 -11.79 %
Quick Ratio 0 0 % 1.16
Shareholders Equity -23.51 28.46 %
Debt to EBITDA -0.582 -1314.85 %


Historical Valuation Ratios of CytomX Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of CytomX Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of CytomX Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of CytomX Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)